Medical device company Uroplasty (NSDQ:UPI) will publish the results of a 3-year study on percutaneous tibial nerve stimulation in treatment of overactive bladder. The findings are slated to appear in the June edition of the The Journal of Urology.
Study patients received an average of 1.1 treatments per month and experienced improved outcomes, including reduced voiding frequency and acute urges to urinate, according to a press release.
The STEP study, led by Kenneth Peters of the urology department of Beaumont Hospital in Royal Oak, Mich., featured Uroplasty’s Urgent PC Neuromodulation system.
"This study demonstrates that with on-going therapy OAB patients can continue to sustain improvement in their OAB symptoms. This is a chronic condition for which there is currently no cure," said Peters in prepared remarks issued earlier this month. "With continuing therapy, patients’ symptoms can be controlled at a level that positively impacts their quality of life. The recent AUA/SUFU OAB Guidelines affirm that for those patients for whom OAB drug therapy and other conservative therapies have not worked, PTNS is an ideal option."